CME
| Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base. | /cme/Chemotherapy_for_Women_With_Heavily_Pre_treated_Metastatic_Breast_Cancer_A_Review_of_the_Evidence_Base.html/cme/Chemotherapy_for_Women_With_Heavily_Pre_treated_Metastatic_Breast_Cancer_A_Review_of_the_Evidence_Base.htmltcm:8-282050-64Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base.Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base.2012071720120717Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base.Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base.An interactive CME activity provided by the Elsevier Office of Continuing Medical EducationAn interactive CME activity provided by the Elsevier Office of Continuing Medical EducationCMECME1.01.0201309302013 Sept 30InteractiveBreastTreatmentChemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base. An interactive CME activity provided by the Elsevier Office of Continuing Medical Education The goals of this activity are to increase oncologists’ knowledge of the newest therapies and improve their competence in incorporating this knowledge into treatment planning. Duration February 12, 2012 to January 31, 2013 Credits A maximum of 1.0 AMA PRA Category 1 Credit™ Faculty Christopher Twelves, MD | Linda T. Vahdat, MD This course is not part of OncologySTAT. By clicking the button below you will be leaving this website. Chemotherapy for Women With Heavily Pre-treated Metastatic Breast Cancer. A Review of the Evidence Base. An interactive CME activity provided by the Elsevier Office of Continuing Medical Education The goals of this activity are to increase oncologists’ knowledge of the newest therapies and improve their competence in incorporating this knowledge into treatment plannin1 |  |
An interactive CME activity provided by the Elsevier Office of Continuing Medical Education | |
|
News
| Age Ups Risk of Other Cancers in Breast Cancer Survivors | /news/Age_Ups_Risk_of_Other_Cancers_in_Breast_Cancer_Survivors_US.html/news/Age_Ups_Risk_of_Other_Cancers_in_Breast_Cancer_Survivors_US.htmltcm:8-284422-64Age Ups Risk of Other Cancers in Breast Cancer SurvivorsAge Ups Risk of Other Cancers in Breast Cancer Survivors20121105Age Ups Risk of Other Cancers in Breast Cancer SurvivorsAge Ups Risk of Other Cancers in Breast Cancer SurvivorsS FreemanS Freeman201211052012 Nov 5IMNG Medical MediaIMNG Medical MediaBreastPrevention and ScreeningMANCHESTER, ENGLAND (IMNG) - Older women who are breast cancer survivors have a greater risk of developing additional primary cancers in the long term than those under 65 years of age, according to an analysis of data on more than 100,000 survivors in the United States.Women aged 70-79 years appear to have the highest risk of developing a multiple primary malignancy (MPM), with a crude 10-year incidence of 17.8/10,000 person-years. In comparisons, the rate of risk for survivors younger than 65 was... MANCHESTER, ENGLAND (IMNG) - Older women who are breast cancer survivors have a greater risk of developing additional primary cancers in the long term than those under 65 years of age, according to an analysis of data on more than 100,000 survivors in the United States. Women aged 70-79 years appear to have the highest risk of developing a multiple primary malignancy (MPM), with a crude 10-year incidence of 17.8/10,000 person-years. In comparisons, the rate of risk for survivors younger thNews120 | |
IMNG Medical Media, 2012 Nov 5, S Freeman
| ASCO Update Keeps Breast Cancer Survivor Guidelines Intact | /news/ASCO_Update_Keeps_Breast_Cancer_Survivor_Guidelines_Intact_US.html/news/ASCO_Update_Keeps_Breast_Cancer_Survivor_Guidelines_Intact_US.htmltcm:8-284430-64ASCO Update Keeps Breast Cancer Survivor Guidelines IntactASCO Update Keeps Breast Cancer Survivor Guidelines Intact20121105ASCO Update Keeps Breast Cancer Survivor Guidelines IntactASCO Update Keeps Breast Cancer Survivor Guidelines IntactT HaelleT Haelle201211052012 Nov 5IMNG Medical MediaIMNG Medical MediaBreastPrevention and ScreeningThe American Society of Clinical Oncology has issued updated recommendations for the follow-up care of breast cancer survivors, but made no changes from guidelines released in 2006.The current guidelines include recommendations for all oncologists, primary care providers, and nurses who treat asymptomatic breast cancer survivors. They emphasize physical exams, patient history, and mammography, but discourage routine blood tests, biomarker studies, and other imaging in the absence of symptoms.An American... The American Society of Clinical Oncology has issued updated recommendations for the follow-up care of breast cancer survivors, but made no changes from guidelines released in 2006. The current guidelines include recommendations for all oncologists, primary care providers, and nurses who treat asymptomatic breast cancer survivors. They emphasize physical exams, patient history, and mammography, but discourage routine blood tests, biomarker studies, and other imaging in the absence ofNews120 | |
IMNG Medical Media, 2012 Nov 5, T Haelle
| Cardiac Toxicity Not Seen 25 Years after Breast Radiation | /news/Cardiac_Toxicity_Not_Seen_25_Years_after_Breast_Radiation__US.html/news/Cardiac_Toxicity_Not_Seen_25_Years_after_Breast_Radiation__US.htmltcm:8-284346-64Cardiac Toxicity Not Seen 25 Years after Breast Radiation Cardiac Toxicity Not Seen 25 Years after Breast Radiation 20121101Cardiac Toxicity Not Seen 25 Years after Breast Radiation Cardiac Toxicity Not Seen 25 Years after Breast RadiationN OsterweilN Osterweil201211012012 Nov 1IMNG Medical MediaIMNG Medical MediaBreastTreatmentASTRO 2012BOSTON (IMNG) - Here's heartening news that physicians can convey to breast cancer survivors: Modern breast irradiation did not appear to cause late-term cardiac toxicity in a study that examined women a quarter of a century after they were treated.Investigators found no significant differences in Framingham Heart Study risk scores, hemodynamic parameters, pericardial thickening, or heart failure among 50 women who had been randomized in the 1970s and 1980s to either mastectomy or breast-conserving... BOSTON (IMNG) - Here's heartening news that physicians can convey to breast cancer survivors: Modern breast irradiation did not appear to cause late-term cardiac toxicity in a study that examined women a quarter of a century after they were treated. Investigators found no significant differences in Framingham Heart Study risk scores, hemodynamic parameters, pericardial thickening, or heart failure among 50 women who had been randomized in the 1970s and 1980s to either mastectomy or breastNews120 | |
IMNG Medical Media, 2012 Nov 1, N Osterweil
| Triple-Negative Breast Cancer Shows Less Aggressive Biology in Elderly | /news/TripleNegative_Breast_Cancer_Shows_Less_Aggressive_Biology_in_Elderly_US.html/news/TripleNegative_Breast_Cancer_Shows_Less_Aggressive_Biology_in_Elderly_US.htmltcm:8-284360-64Triple-Negative Breast Cancer Shows Less Aggressive Biology in ElderlyTriple-Negative Breast Cancer Shows Less Aggressive Biology in Elderly20121102Triple-Negative Breast Cancer Shows Less Aggressive Biology in ElderlyTriple-Negative Breast Cancer Shows Less Aggressive Biology in ElderlyS FreemanS Freeman201211012012 Nov 1IMNG Medical MediaIMNG Medical MediaBreastTreatmentMANCHESTER, ENGLAND (IMNG) - Older women with primary, operable, triple-negative breast cancer may have less aggressive tumor biology despite being treated for larger tumors than their younger counterparts, new data suggest.Tumor samples taken from women aged 70 years or older were found to be of lower grade with significantly lower expression of the tumor markers Ki67 and p53 than seen in younger women, investigators reported at the annual meeting of the International Society of Geriatric Oncology... MANCHESTER, ENGLAND (IMNG) - Older women with primary, operable, triple-negative breast cancer may have less aggressive tumor biology despite being treated for larger tumors than their younger counterparts, new data suggest. Tumor samples taken from women aged 70 years or older were found to be of lower grade with significantly lower expression of the tumor markers Ki67 and p53 than seen in younger women, investigators reported at the annual meeting of the International Society of GeriatrNews120 | |
IMNG Medical Media, 2012 Nov 1, S Freeman
| Older Women Lived Longer With Radiotherapy After Lumpectomy | /news/Older_Women_Lived_Longer_With_Radiotherapy_After_Lumpectomy__US.html/news/Older_Women_Lived_Longer_With_Radiotherapy_After_Lumpectomy__US.htmltcm:8-284334-64Older Women Lived Longer With Radiotherapy After Lumpectomy Older Women Lived Longer With Radiotherapy After Lumpectomy 20121031Older Women Lived Longer With Radiotherapy After LumpectomyOlder Women Lived Longer With Radiotherapy After LumpectomyN OsterweilN Osterweil201210312012 Oct 31IMNG Medical MediaIMNG Medical MediaBreastTreatmentASTRO 2012BOSTON (IMNG) - A review of data on nearly 30,000 women suggests older age by itself should not be a barrier to radiotherapy after lumpectomy for early-stage breast cancer.Older patients treated with both modalities had higher rates of overall and breast cancer - specific survival at 5 and 10 years compared with women who underwent lumpectomy alone , investigators reported at the annual meeting of the American Society for Radiation Oncology."The improvement in cause-specific survival with the addition... BOSTON (IMNG) - A review of data on nearly 30,000 women suggests older age by itself should not be a barrier to radiotherapy after lumpectomy for early-stage breast cancer. Older patients treated with both modalities had higher rates of overall and breast cancer - specific survival at 5 and 10 years compared with women who underwent lumpectomy alone , investigators reported at the annual meeting of the American Society for Radiation Oncology. "The improvement in cause-specific survivalNews120 | |
IMNG Medical Media, 2012 Oct 31, N Osterweil
| Screening Cuts Breast Cancer Deaths by 20% | /news/Screening_Cuts_Breast_Cancer_Deaths_by_20_US.html/news/Screening_Cuts_Breast_Cancer_Deaths_by_20_US.htmltcm:8-284308-64Screening Cuts Breast Cancer Deaths by 20%Screening Cuts Breast Cancer Deaths by 20%20121029Screening Cuts Breast Cancer Deaths by 20%Screening Cuts Breast Cancer Deaths by 20%J SmithJ Smith201210292012 Oct 29IMNG Medical MediaIMNG Medical MediaBreastPrevention and ScreeningWomen offered breast cancer screening have a 20% lower relative risk of dying from breast cancer than women not invited to participate in screening, a epidemiologic study in the Lancet from the United Kingdom has found.The study also found that women invited to screening are also more likely to be overdiagnosed, meaning that they are treated surgically for tumors that, if not for screening, would have caused no illness and remained undetected. The researchers cautioned, however, that their findings... Women offered breast cancer screening have a 20% lower relative risk of dying from breast cancer than women not invited to participate in screening, a epidemiologic study in the Lancet from the United Kingdom has found. The study also found that women invited to screening are also more likely to be overdiagnosed, meaning that they are treated surgically for tumors that, if not for screening, would have caused no illness and remained undetected. The researchers cautioned, however, that theNews120 | |
IMNG Medical Media, 2012 Oct 29, J Smith
| FDA Panel Supports Approval of Hologic's C-View Software for 3D Digital Mammography | /news/FDA_Panel_Supports_Approval_of_Hologics_CView_Software_for_3D_Digital_Mammography.html/news/FDA_Panel_Supports_Approval_of_Hologics_CView_Software_for_3D_Digital_Mammography.htmltcm:8-284241-64FDA Panel Supports Approval of Hologic's C-View Software for 3D Digital MammographyFDA Panel Supports Approval of Hologic's C-View Software for 3D Digital Mammography20121025FDA Panel Supports Approval of Hologic's C-View Software for 3D Digital MammographyFDA Panel Supports Approval of Hologic's C-View Software for 3D Digital MammographyR KernR Kern201210252012 Oct 25IMNG Medical MediaIMNG Medical MediaBreastPrevention and ScreeningThe benefits of Hologic’s C-View software for three-dimensional digital mammography exams with less radiation than the current process outweigh the risks, FDA’s Radiological Devices panel concluded in a 9-1 vote Oct. 24. The advisory panel also voted 9-1 that C-View demonstrated reasonable assurance of safety and efficacy.C-View is an imaging algorithm add-on for Hologic’s currently available Selenia Dimensions 3D digital mammography system that is designed to eliminate the need to perform a separate... The benefits of Hologic’s C-View software for three-dimensional digital mammography exams with less radiation than the current process outweigh the risks, FDA’s Radiological Devices panel concluded in a 9-1 vote Oct. 24. The advisory panel also voted 9-1 that C-View demonstrated reasonable assurance of safety and efficacy. C-View is an imaging algorithm add-on for Hologic’s currently available Selenia Dimensions 3D digital mammography system that is designed to eliminate the need to perNews120 | |
IMNG Medical Media, 2012 Oct 25, R Kern
| NICE Backs Xgeva for Oncology But Excludes Prostate Cancer Indication | /news/NICE_Backs_Xgeva_for_Oncology_But_Excludes_Prostate_Cancer_Indication.html/news/NICE_Backs_Xgeva_for_Oncology_But_Excludes_Prostate_Cancer_Indication.htmltcm:8-284247-64NICE Backs Xgeva for Oncology But Excludes Prostate Cancer IndicationNICE Backs Xgeva for Oncology But Excludes Prostate Cancer Indication20121025NICE Backs Xgeva for Oncology But Excludes Prostate Cancer IndicationNICE Backs Xgeva for Oncology But Excludes Prostate Cancer IndicationF KermaniF Kermani201210242012 Oct 24The Pink Sheet DailyThe Pink Sheet DailyBreastProstateSkeletal Related EventTreatmentSkeletal-Related EventsIn a rare occurrence for any drug navigating its way through the UK’s reimbursement system, Amgen Inc.’s Xgeva (denosumab) for the treatment of skeletal events in some cancer patients has fairly flown through the National Institute for Health and Clinical Excellence’s evaluation process. Although the company did not get everything it wanted from the health-cost regulator, the discount Amgen offered the NHS means that it can now rest assured that the uptake of Xgeva is only a brief matter of time. NICE... In a rare occurrence for any drug navigating its way through the UK’s reimbursement system, Amgen Inc.’s Xgeva (denosumab) for the treatment of skeletal events in some cancer patients has fairly flown through the National Institute for Health and Clinical Excellence’s evaluation process. Although the company did not get everything it wanted from the health-cost regulator, the discount Amgen offered the NHS means that it can now rest assured that the uptake of Xgeva is only a brief mattNews120 | |
The Pink Sheet Daily, 2012 Oct 24, F Kermani | |
|
Expert Opinion
| My Approach to Endocrine Therapy in Breast Cancer—Part I | /viewpoints/my-approach/My_Approach_to_Endocrine_Therapy_in_Breast_Cancer_Part_I.html/viewpoints/my-approach/My_Approach_to_Endocrine_Therapy_in_Breast_Cancer_Part_I.htmltcm:8-283642-64My Approach to Endocrine Therapy in Breast Cancer—Part IMy Approach to Endocrine Therapy in Breast Cancer—Part I20120918My Approach to Endocrine Therapy in Breast Cancer—Part IMy Approach to Endocrine Therapy in Breast Cancer—Part IDaniel Hayes, MDDaniel Hayes, MD201209182012 Sept 18Interview by L Scott ZoellerInterview by L Scott ZoellerBreastER Positive BreastTreatmentIn Part I of this interview, Dr. Hayes discusses personalization and the optimal sequence of endocrine therapy in breast cancer. In Part II, Dr. Hayes discusses early vs late recurrence, extended therapy, and the potential for combination therapy.Personalized TherapyOncologySTAT: Would you discuss how modern adjuvant endocrine therapy is becoming increasingly personalized in breast cancer?Dr. Hayes: That depends on what one means by "personalized." My answer is I don’t think it is. I think we got... In Part I of this interview, Dr. Hayes discusses personalization and the optimal sequence of endocrine therapy in breast cancer. In Part II, Dr. Hayes discusses early vs late recurrence, extended therapy, and the potential for combination therapy. Personalized Therapy OncologySTAT: Would you discuss how modern adjuvant endocrine therapy is becoming increasingly personalized in breast cancer? Dr. Hayes: That depends on what one means by "personalized." My answer is I don’t think it is. I thiMy Approach26 | |
Interview by L Scott Zoeller, 2012 Sept 18, Daniel Hayes, et al | |
|
Journal Scans: Research
| Lapatinib Plus Capecitabine in Brain Metastases from HER2+ Breast Cancer | /journals/journal_scans/Lapatinib_Plus_Capecitabine_in_Patients_With_Previously_Untreated_Brain_Metastases_from_HER2-positive_Metastatic_Breast_Cancer_(LANDSCAPE)_A_Single-group_Phase_2_Study.html/journals/journal_scans/Lapatinib_Plus_Capecitabine_in_Patients_With_Previously_Untreated_Brain_Metastases_from_HER2-positive_Metastatic_Breast_Cancer_(LANDSCAPE)_A_Single-group_Phase_2_Study.htmltcm:8-284473-64Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases from HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-group Phase 2 StudyLapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases from HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-group Phase 2 Study20121107Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases from HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-group Phase 2 StudyLapatinib Plus Capecitabine in Brain Metastases from HER2+ Breast CancerT Bachelot, G Romieu, M Campone, et alT Bachelot, G Romieu, M Campone, et al201211012012 Nov 1Lancet OncolLancet OncolBreastTreatmentNeurologic ComplicationsIn an update of the LANDSCAPE Phase II trial, a response rate of 65.9% was achieved with the combination of lapatinib and capecitabine when used as first-line therapy for HER2+ breast cancer with brain metastases. Abstract Background: Brain metastases occur in 30–50% of patients with metastatic HER2-positive breast cancer. In the case of diffuse brain metastases, treatment is based on whole brain radiotherapy (WBRT). Few systemic options are available. We aimed to investigate the combination of lapatinib plus capecitabine for the treatment of previously untreated brain metastases from HER2-positive breast cancer.Methods: In this single-arm phase 2, open-label, multicentre study, eligible patients had HER2-positive... Abstract Background: Brain metastases occur in 30–50% of patients with metastatic HER2-positive breast cancer. In the case of diffuse brain metastases, treatment is based on whole brain radiotherapy (WBRT). Few systemic options are available. We aimed to investigate the coJournal Scans149 | |
Lancet Oncol, 2012 Nov 1, T Bachelot, et al
| Validating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence | /journals/journal_scans/Validating_a_Prognostic_Scoring_System_for_Postmastectomy_Locoregional_Recurrence_in_Breast_Cancer.html/journals/journal_scans/Validating_a_Prognostic_Scoring_System_for_Postmastectomy_Locoregional_Recurrence_in_Breast_Cancer.htmltcm:8-284475-64Validating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence in Breast CancerValidating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence in Breast Cancer20121107Validating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence in Breast CancerValidating a Prognostic Scoring System for Postmastectomy Locoregional RecurrenceSHC Cheng, SY Tsai, B-L Yu, et alSHC Cheng, SY Tsai, B-L Yu, et al201211012012 Nov 1Int J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysBreastDiagnosis and StagingResearchers sought to validate a previous scoring system to determine the necessity of postmastectomy radiation therapy in breast cancer patients with 1 to 3 positive lymph nodes. Abstract Purpose: This study is designed to validate a previously developed locoregional recurrence risk (LRR) scoring system and further define which groups of patients with breast cancer would benefit from postmastectomy radiation therapy (PMRT).Methods and Materials: An LRR risk scoring system was developed previously at our institution using breast cancer patients initially treated with modified radical mastectomy between 1990 and 2001. The LRR score comprised 4 factors: patient age, lymphovascular invasion,... Abstract Purpose: This study is designed to validate a previously developed locoregional recurrence risk (LRR) scoring system and further define which groups of patients with breast cancer would benefit from postmastectomy radiation therapy (PMRT). Methods and Materials: An LRR risk scoring system Journal Scans149 | |
Int J Radiat Oncol Biol Phys, 2012 Nov 1, SHC Cheng, et al
| PTEN Loss Common in Trastuzumab Resistance in Breast Cancer | /journals/journal_scans/Frequent_Mutational_Activation_of_the_PI3K-AKT_Pathway_in_Trastuzumab-Resistant_Breast_Cancer.html/journals/journal_scans/Frequent_Mutational_Activation_of_the_PI3K-AKT_Pathway_in_Trastuzumab-Resistant_Breast_Cancer.htmltcm:8-284362-64Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerFrequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer20121102Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerPTEN Loss Common in Trastuzumab Resistance in Breast CancerS Chandarlapaty, RA Sakr, D Giri, et alS Chandarlapaty, RA Sakr, D Giri, et al201210232012 Oct 23Clin Cancer ResClin Cancer ResBreastTreatmentIn a prospective study, a high percentage of trastuzumab-resistant HER2+ breast tumors had PTEN loss and activating mutations of the PI3K/AKT pathway, while loss of HER2 overexpression was rare. SUMMARY OncologySTAT Editorial Team Despite the efficacy of trastuzumab therapy in metastatic HER2-positive breast cancer, almost all patients eventually have disease progression. Determining the molecular basis for trastuzumab resistance has been hampered in part because of the difficulty in acquiring tumor samples from patients who progress while on trastuzumab. Possible explanations for trastuzumab resistance, based on retrospective studies and laboratory models, include activation of the PI3K/AKT pathway, in response to either... SUMMARY OncologySTAT Editorial Team Despite the efficacy of trastuzumab therapy in metastatic HER2-positive breast cancer, almost all patients eventually have disease progression. Determining the molecular basis for trastuzumab resistance has been hampered in part Journal Scans149 | |
Clin Cancer Res, 2012 Oct 23, S Chandarlapaty, et al
| Treatment Response Biomarker Identified in Triple-Negative Breast Cancer | /journals/journal_scans/Thymosin_Beta_15A_TMSB15A_is_a_Predictor_of_Chemotherapy_Response_in_Triple_Negative_Breast_Cancer.html/journals/journal_scans/Thymosin_Beta_15A_TMSB15A_is_a_Predictor_of_Chemotherapy_Response_in_Triple_Negative_Breast_Cancer.htmltcm:8-284440-64Thymosin Beta 15A (TMSB15A) is a Predictor of Chemotherapy Response in Triple-Negative Breast CancerThymosin Beta 15A (TMSB15A) is a Predictor of Chemotherapy Response in Triple-Negative Breast Cancer20121106Thymosin Beta 15A (TMSB15A) is a Predictor of Chemotherapy Response in Triple-Negative Breast CancerTreatment Response Biomarker Identified in Triple-Negative Breast CancerS Darb-Esfahani, R Kronenwett, G von Minckwitz, et alS Darb-Esfahani, R Kronenwett, G von Minckwitz, et al201210182012 Oct 18Br J CancerBr J CancerBreastEpidemiology and EtiologyTreatmentInvestigators validated thymosin beta 15A levels as predictive of response to neoadjuvant chemotherapy in patients with triple-negative breast cancer. Abstract Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed.Methods: Using a training/validation approach for detection of predictive biomarkers in HER2-negative breast cancer, pre-therapeutic core biopsies from four independent cohorts were investigated: Gene array data were analysed in fresh frozen samples of two cohorts (n=86 and n=55). Quantitative reverse transcription polymerase chain reaction (qRT–PCR) was... Abstract Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed. Methods: Using a training/validation approach for detection of predictive biomarkers in HER2-negative breast cancer, pre-therapeutic core biopsies from four independent cohorts wJournal Scans149 | |
Br J Cancer, 2012 Oct 18, S Darb-Esfahani, et al
| Latest Approaches to Imaging Common Malignancies | /journals/journal_scans/Advances_in_Oncologic_Imaging_Update_on_Five_Common_Cancers.html/journals/journal_scans/Advances_in_Oncologic_Imaging_Update_on_Five_Common_Cancers.htmltcm:8-284396-64Advances in Oncologic Imaging—Update on Five Common CancersAdvances in Oncologic Imaging—Update on Five Common Cancers20121105Advances in Oncologic Imaging—Update on Five Common CancersLatest Approaches to Imaging Common MalignanciesO Akin, SB Brennan, DD Dershaw, et alO Akin, SB Brennan, DD Dershaw, et al201210152012 Oct 15CA Cancer J ClinCA Cancer J ClinYesBreastColon and RectumHodgkin's LymphomaLungNon-Hodgkin's LymphomaProstateDiagnosis and StagingRecent progress in imaging technologies has provided opportunities for improved patient care. This article outlines relevant advances in breast, lung, prostate, and colorectal cancers and lymphoma. Abstract Imaging has become a pivotal component throughout a patient's encounter with cancer, from initial disease detection and characterization through treatment response assessment and posttreatment follow-up. Recent progress in imaging technology has presented new opportunities for improving clinical care. This article provides updates on the latest approaches to imaging of 5 common cancers: breast, lung, prostate, and colorectal cancers, and lymphoma. Abstract Imaging has become a pivotal component throughout a patient's encounter with cancer, from initial disease detection and characterization through treatment response assessment and posttreatment follow-up. Recent progress in imaging technology has presented new opportunities for improving clinical care. This article provides updatesJournal Scans149 |  |
CA Cancer J Clin, 2012 Oct 15, O Akin, et al | |
|
Journal Scans: Review
| Epithelial–Mesenchymal Transition and Breast Cancer | /journals/review_articles/YCTRV/Epithelial_Mesenchymal_Transition_and_Breast_Cancer_Role_Molecular_Mechanisms_and_Clinical_Impact.html/journals/review_articles/YCTRV/Epithelial_Mesenchymal_Transition_and_Breast_Cancer_Role_Molecular_Mechanisms_and_Clinical_Impact.htmltcm:8-282070-64Epithelial–Mesenchymal Transition and Breast Cancer: Role, Molecular Mechanisms and Clinical ImpactEpithelial–Mesenchymal Transition and Breast Cancer: Role, Molecular Mechanisms and Clinical Impact20120718Epithelial–Mesenchymal Transition and Breast Cancer: Role, Molecular Mechanisms and Clinical ImpactEpithelial–Mesenchymal Transition and Breast CancerC Foroni, M Broggini, D Generali, G DamiaC Foroni, M Broggini, D Generali, G DamiaYes201210012012 Oct 1Cancer Treat RevCancer Treat RevBreastEpidemiology and EtiologyAbstract Epithelial–mesenchymal transition (EMT) is defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. In this process, cells acquire molecular alterations that facilitate dysfunctional cell–cell adhesive interactions and junctions. These processes may promote cancer cell progression and invasion into the surrounding microenvironment. Such transformation has implications in progression of breast carcinoma to metastasis, and increasing evidence supports the fact... Abstract Epithelial–mesenchymal transition (EMT) is defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. In this process, cells acquire molecular alterations that facilitate dysfunctional cell–cell adhesive interactions and junctions. These processes may promote cancer cell progression and invasion into the surrounding microenvironment. Such transformation has implications in progression of breast carcinoma to metastasis, and increasinEditors ChoiceReview Articles38 | |
Cancer Treat Rev, 2012 Oct 1, C Foroni, et al
| mTOR Inhibitors in Breast Cancer: A Systematic Review | /journals/review_articles/GYNO/mTOR_Inhibitors_in_Breast_Cancer_A_Systematic_Review.html/journals/review_articles/GYNO/mTOR_Inhibitors_in_Breast_Cancer_A_Systematic_Review.htmltcm:8-283752-64mTOR Inhibitors in Breast Cancer: A Systematic ReviewmTOR Inhibitors in Breast Cancer: A Systematic Review20120926mTOR Inhibitors in Breast Cancer: A Systematic ReviewmTOR Inhibitors in Breast Cancer: A Systematic ReviewF Zagouri, TN Sergentanis, D Chrysikos, et alF Zagouri, TN Sergentanis, D Chrysikos, et alYes201209082012 Sept 8Gynecol OncolGynecol OncolBreastTreatmentAbstract PI3K/AKT/mTOR pathway is a crucial mediator of tumor progression. As the PI3K/Akt pathway is heavily deregulated in breast cancer, the application of mTOR inhibitors in breast cancer patients seems warranted. This is the first systematic review according to PRISMA guidelines to synthesize all available data of mTOR inhibitors in all subcategories of breast cancer. The search strategy retrieved 16 studies evaluating everolimus (1492 patients), seven studies examining temsirolimus (1245 patients),... Abstract PI3K/AKT/mTOR pathway is a crucial mediator of tumor progression. As the PI3K/Akt pathway is heavily deregulated in breast cancer, the application of mTOR inhibitors in breast cancer patients seems warranted. This is the first systematic review according to PRISMA guidelines to synthesize all available data of mTOR inhibitors in all subcategories of breast cancer. The search strategy retrieved 16 studies evaluating everolimus (1492 patients), seven studies examining temsiroEditors ChoiceReview Articles38 | |
Gynecol Oncol, 2012 Sept 8, F Zagouri, et al
| Intensity-Modulated Radiotherapy in the Treatment of Breast Cancer | /journals/review_articles/CLON/Intensity-Modulated_Radiotherapy_in_the_Treatment_of_Breast_Cancer.html/journals/review_articles/CLON/Intensity-Modulated_Radiotherapy_in_the_Treatment_of_Breast_Cancer.htmltcm:8-283579-64Intensity-Modulated Radiotherapy in the Treatment of Breast CancerIntensity-Modulated Radiotherapy in the Treatment of Breast Cancer20120913Intensity-Modulated Radiotherapy in the Treatment of Breast CancerIntensity-Modulated Radiotherapy in the Treatment of Breast CancerI Dayes, RB Rumble, J BowenI Dayes, RB Rumble, J BowenYes201209012012 Sept 1Clin OncolClin OncolBreastTreatmentAbstract Intensity-modulated radiotherapy (IMRT) is a newer method of radiotherapy that uses beams with multiple intensity levels for any single beam, allowing concave dose distributions and tighter margins than those possible using conventional radiotherapy. IMRT is ideal for treating complex treatment volumes and avoiding close proximity organs at risk that may be dose limiting and provides increased tumour control through an escalated dose and reduces normal tissue complications through organ at risk sparing.... Abstract Intensity-modulated radiotherapy (IMRT) is a newer method of radiotherapy that uses beams with multiple intensity levels for any single beam, allowing concave dose distributions and tighter margins than those possible using conventional radiotherapy. IMRT is ideal for treating complex treatment volumes and avoiding close proximity organs at risk that may be dose limiting and provides increased tumour control through an escalated dose and reduces normal tissue compliEditors ChoiceReview Articles38 | |
Clin Oncol, 2012 Sept 1, I Dayes, et al | |
|
Videos
| Newer, More Costly Drugs No Better Than Paclitaxel | /video/ASCO_2012/Newer_More_Costly_Drugs_No_Better_Than_Paclitaxel.html/video/ASCO_2012/Newer_More_Costly_Drugs_No_Better_Than_Paclitaxel.htmltcm:8-280638-64Newer, More Costly Drugs No Better Than PaclitaxelNewer, More Costly Drugs No Better Than Paclitaxel20120611Newer, More Costly Drugs No Better Than PaclitaxelNewer, More Costly Drugs No Better Than Paclitaxel201206032012 Jun 3IMNG Medical MediaIMNG Medical Media/Images/Hope_Rugo_tcm8-280633.jpgBreastTreatmentASCO 2012A phase III randomized trial found that weekly administration of either of two newer and significantly more costly agents, nanoparticle albumin bound ("nab") paclitaxel (Abraxane) and ixabepilone (Ixempra), was not superior to standard weekly dosing of paclitaxel as first-line therapy for locally advanced or metastatic breast cancer. Furthermore, paclitaxel appears to offer better progression-free survival (PFS) than ixabepilone and fewer toxicities than nab-paclitaxel in this setting. /Images/Hope_Rugo_tcm8-280633.jpg See related videos to: ASCO 2012 Copyright © 2012 International Medical News Group Subscribe Now » Videos13 |  |
IMNG Medical Media, 2012 Jun 3, |
